Impella CP microaxial flow pump supports complete revascularisation during high-risk PCI, but standard implantation often leads to vascular complications. This article explores an initial experience with a sheathless implantation technique, which shows promise as a feasible and safe alternative.

There has been significant expansion in the field of structural heart diseases in the last couple of years, generating an extensive body of evidence and warranting an update to the 2017 Guidelines. Mirvat Alasnag provides an analysis of the updates included in this new document - a joint...

Paris, France. 21 May 2021.  Since 1989, EuroPCR has constantly pioneered innovative educational tools and formats to help the interventional cardiovascular community effectively share their knowledge, skills and practice. Rising up to the challenge of the pandemic, the 31st annual edition was fundamentally rethought, reshaped and...

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Jonathan Curio and Alex Sticchi provide their take on this clinical trial which was presented by Paul Sorajja at the American College of Cardiology Scientific Session (ACC.23/WCC).

Jonathan Curio provides his take on the MitrAI score study which was presented by Luigi Biasco at ESC Congress 2024 in London.

Mirvat Alasnag provides her take on the ECMO-CS trial, which was presented during AHA 2022 in Chicago, and simultaneously published in Circulation. 

Mirvat Alasnag provides her take on the Altshock-2 randomized clinical trial which was presented by Alice Sacco at ACC.25 in Chicago.

Nicola Ryan provides her take on the results of TAILORED-CHIP presented by Duk-Woo Park at the ESC Congress 2025 in Madrid.

Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.

What’s the safest approach when surgical options are off the table? This real-life case shows how complex coronary revascularsation and TAVI were performed in a single session, supported by Impella.

Explore the rationale behind the sequence, the device choices, and the outcome in a high-risk patient with...

Mirvat Alasnag provides her take on the CLEAR SYNERGY trial presented by Sanjit S Jolly at AHA 2024 in Chicago.

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Real-world case report illustrating the benefits of the Portico with FlexNav TAVI system.

PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB trials were presented at TCT Connect 2020. Hector Garcia-Garcia provides a summary of the key messages.

At TCT Connect 2020, Late-Breaking Trial Session II, the primary results of the Safety and Efficacy Comparison of Two TAVI Systems in a Prospective Randomized Evaluation (SCOPE) 2 trial were presented and simultaneously published in Circulation. Daniele Giacoppo provides a summary of the trial.

Transcatheter structural procedures are dramatically increasing in daily practice. Approaching hostile cardiac anatomy may increase the risk of device dislodgment and/or malposition. In such situations, the use of a snare catheter is pivotal to enhance device trackability.

Mirvat Alasnag provides her take on the TEER Shock study which was presented at TCT 2022 by Mohamad A. Alkhouli.

Mirvat Alasnag provides her take on OPTION-STEMI, presented by Youngkeun Ahn at ESC Congress 2025 in Madrid.

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.